Advertisement
Screener

RELMADA THERAPEUTICS, INC. (RLMD) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

2.9 / 5 stars · 23/40 Roast Me

RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 4.76 million shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2024-11-07

  • RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-09-30 was 0.00 shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month
2024-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
4.76M shares
10-Q · filed 2024-11-07
2024-06-304.76M shares
10-Q · filed 2024-08-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63